Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $130 to $133.
August 05, 2024 | 7:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Blueprint Medicines and raises the price target from $130 to $133.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100